Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
23 February 2023 - 12:00AM
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:
CWY) (“Clearmind” or “the company"), a biotech company focused on
the discovery and development of novel psychedelic-derived
therapeutics to solve major under-treated health problems, today
announced that it has filed three provisional patent applications
with the United States Patent and Trademark Office (USPTO), for
unique combinations of future psychedelic-based compounds, as
part of its ongoing collaboration with pharmaceutical company
SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders of the central nervous system.
The patent applications refer to novel
proprietary combinations of 3,4-Methylenedioxymethamphetamine
(MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide
(PEA), the active ingredient of SciSparc's proprietary
CannAmide™.
The applications reflect Clearmind’s
strategy of strengthening its IP portfolio to broaden the
therapeutic psychedelic toolbox for patients with mental health
disorders that require transformative medicines, and
developing treatments that offer synergy, efficacy and safety while
reducing cost.
"Combined with our positive preclinical data and
the successful proof-of-concept for the combination of
psychedelic-based molecules with SciSparc's CannAmide, the new
patent applications pave the way for us to innovate treatment
options for unmet patient needs, ," said Clearmind's CEO Dr. Adi
Zuloff-Shani, PhD. "We are proud to be leaders in the psychedelic
industry with the most robust IP portfolio consisting of granted
and pending patents. We plan to continue to be pioneers in the
field of novel psychedelic compounds and treatments."
Clearmind has a broad IP footprint in the
psychedelic space, with 29 patents in 13 patent families, of which
9 have been granted in major jurisdictions like the US, Europe,
China, and India.
Overall, as part of this collaboration, six
other patent applications have been filed by Clearmind with the
USPTO for various combinations, three of them for the combination
of SciSparc’s PEA with Clearmind’s MEAI compound
(5-methoxy-2-aminoindane) for the treatment of alcohol use
disorder, treatment of cocaine addiction and treatment of obesity
and its related metabolic disorders, and recently for novel
proprietary combinations of lysergic acid diethylamide (“LSD”),
psilocybin, and N,N-dimethyltryptamine (“DMT”) and SciSparc’s PEA,
the active ingredient of its proprietary CannAmide™.
About Clearmind Medicine
Inc.
Clearmind is a psychedelic pharmaceutical
biotech company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The company’s intellectual portfolio currently
consists of 13 patent families. The company intends to seek
additional patents for its compounds whenever warranted and will
remain opportunistic regarding the acquisition of additional
intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on
Nasdaq and the Canadian Securities Exchange under the symbol "CMND"
and the Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
About SciSparc Ltd. (Nasdaq:
SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of
Tourette Syndrome, for the treatment of Alzheimer's disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of autism spectrum disorder and status epilepticus.
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act and other securities laws. Words such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates”
and similar expressions or variations of such words are intended to
identify forward-looking statements. Forward-looking statements are
not historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. In addition, we cannot assure that any patent will
issue as a result of a pending patent application or, if issued,
whether it will issue in a form that will be advantageous to us.
Forward-looking statements are subject to risks and uncertainties
that could cause actual performance or results to differ materially
from those expressed in the forward-looking statements. For a more
detailed description of the risks and uncertainties affecting the
Company, reference is made to the Company’s reports filed from time
to time with the Securities and Exchange Commission (“SEC”),
including, but not limited to, the risks detailed in the Company’s
annual report on Form 20-F filed with the SEC on February 6, 2023.
Forward-looking statements speak only as of the date the statements
are made. The Company assumes no obligation to update
forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other
factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update
one or more forward-looking statements, no inference should be
drawn that the Company will make additional updates with respect
thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a
convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not
responsible for the contents of third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Apr 2024 to May 2024
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From May 2023 to May 2024